Published in World J Gastroenterol on December 21, 2005
Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity (2007) 5.73
Hepatitis B virus-induced oncogenesis. World J Gastroenterol (2007) 1.82
Down-regulation of long non-coding RNA GAS5 is associated with the prognosis of hepatocellular carcinoma. Int J Clin Exp Pathol (2014) 1.54
Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer (2008) 1.40
Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer (2008) 1.28
Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther (2010) 1.18
Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med (2007) 1.05
Current management of advanced hepatocellular carcinoma. Gastrointest Cancer Res (2008) 1.04
Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus. Surg Today (2013) 1.01
Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS One (2012) 0.99
Therapeutics Based on microRNA: A New Approach for Liver Cancer. Curr Genomics (2010) 0.96
Identification of pathogenesis-related microRNAs in hepatocellular carcinoma by expression profiling. Oncol Lett (2012) 0.95
Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Mol Pharmacol (2009) 0.94
MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int (2014) 0.94
The chemopreventive effect of Ginkgo biloba and Silybum marianum extracts on hepatocarcinogenesis in rats. Cancer Cell Int (2011) 0.90
Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol (2015) 0.89
Identification of miR-423 and miR-499 polymorphisms on affecting the risk of hepatocellular carcinoma in a large-scale population. Genet Test Mol Biomarkers (2014) 0.88
Identification of recurrence related microRNAs in hepatocellular carcinoma after surgical resection. Int J Mol Sci (2013) 0.87
Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases. J Med Chem (2006) 0.86
Potent, tumor-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector. Gene Ther (2011) 0.85
Emerging role of microRNA in hepatocellular carcinoma (Review). Oncol Lett (2014) 0.84
Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods. Eur J Med Res (2013) 0.84
Hypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapy. J Control Release (2013) 0.83
Serum biomarkers identification by mass spectrometry in high-mortality tumors. Int J Proteomics (2013) 0.83
Klotho: a tumor suppressor and modulator of the Wnt/β-catenin pathway in human hepatocellular carcinoma. Lab Invest (2015) 0.82
Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol (2012) 0.82
Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol (2010) 0.80
Development of MicroRNA Therapeutics for Hepatocellular Carcinoma. Diagnostics (Basel) (2013) 0.80
Celecoxib enhances the detoxification of diethylnitrosamine in rat liver cancer. World J Gastroenterol (2009) 0.80
A multicentre controlled study of the InLine radiofrequency ablation device for liver transection. HPB (Oxford) (2007) 0.79
Decreased PCSK9 expression in human hepatocellular carcinoma. BMC Gastroenterol (2015) 0.79
Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy. World J Gastroenterol (2013) 0.79
Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenib. World J Hepatol (2010) 0.79
Indole-3-carbinol inhibits tumorigenicity of hepatocellular carcinoma cells via suppression of microRNA-21 and upregulation of phosphatase and tensin homolog. Biochim Biophys Acta (2014) 0.79
Gene expression profiling of MYC-driven tumor signatures in porcine liver stem cells by transcriptome sequencing. World J Gastroenterol (2015) 0.78
Exosomes as potent regulators of HCC malignancy and potential bio-tools in clinical application. Int J Clin Exp Med (2015) 0.78
The role of (18)F-FDG positron emission tomography in the follow-up of liver tumors treated with (90)Yttrium radioembolization. Am J Nucl Med Mol Imaging (2015) 0.78
Downregulation of KIF1B mRNA in hepatocellular carcinoma tissues correlates with poor prognosis. World J Gastroenterol (2015) 0.77
Analysis of gene expression profiles as a tool to uncover tumor markers of liver cancer progression in a rat model. Biomed Rep (2014) 0.77
Mouse models of liver cancer: Progress and recommendations. Oncotarget (2015) 0.77
Increased gene delivery efficiency and specificity of a lipid-based nanosystem incorporating a glycolipid. Int J Nanomedicine (2014) 0.76
Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma. Clin Proteomics (2016) 0.75
Screening and identification of the tumor-associated antigen CK10, a novel potential liver cancer marker. FEBS Open Bio (2017) 0.75
Preliminary evaluation of indigenous (90) Y-labelled microspheres for therapy of hepatocellular carcinoma. Indian J Med Res (2016) 0.75
Long noncoding RNA ZNFX1-AS1 suppresses growth of hepatocellular carcinoma cells by regulating the methylation of miR-9. Onco Targets Ther (2016) 0.75
Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Transl Gastroenterol Hepatol (2016) 0.75
Embolotherapy in the management of hepatocellular carcinoma. Semin Intervent Radiol (2008) 0.75
Can combination of osteopontin and peritumor-infiltrating macrophages be a prognostic marker of early-stage hepatocellular carcinoma? Hepatobiliary Surg Nutr (2014) 0.75
Upregulation of heat shock protein 70 and the differential protein expression induced by tumor necrosis factor-alpha enhances migration and inhibits apoptosis of hepatocellular carcinoma cell HepG2. Int J Med Sci (2017) 0.75
Expression of protein TARBP1 in human hepatocellular carcinoma and its prognostic significance. Int J Clin Exp Pathol (2015) 0.75
Downregulation of microRNA-132 indicates progression in hepatocellular carcinoma. Exp Ther Med (2016) 0.75
Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol (2015) 0.75
Progress in stem cell-derived technologies for hepatocellular carcinoma. Stem Cells Cloning (2010) 0.75
Trend of hepatocellular carcinoma incidence after Bayesian correction for misclassified data in Iranian provinces. World J Hepatol (2017) 0.75
Evaluation of hepatocellular carcinoma with portal vein tumor thrombosis by CEUS before and after hepatic arterial infusion chemotherapy. J Med Ultrason (2001) (2010) 0.75
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Hepatocellular carcinoma. Lancet (2003) 22.54
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (2002) 9.76
Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36
Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med (2001) 7.71
Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med (2002) 6.64
Increase in primary liver cancer in the UK, 1979-94. Lancet (1997) 6.15
The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med (2003) 6.06
Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med (1997) 6.03
Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med (1996) 6.01
Hepatocellular carcinoma: recent trends in the United States. Gastroenterology (2004) 5.90
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology (1999) 5.70
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2004) 5.40
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology (2003) 4.72
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet (2000) 4.60
Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology (2003) 4.21
Management of hepatitis B: 2000--summary of a workshop. Gastroenterology (2001) 4.17
Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology (2003) 4.13
Cancer: an inflammatory link. Nature (2004) 3.88
Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A (1994) 3.76
EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol (1999) 3.65
Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology (2002) 3.59
Molecular viral oncology of hepatocellular carcinoma. Oncogene (2003) 3.58
Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet (1999) 3.54
Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology (2000) 3.42
Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology (2000) 3.42
Complications of radiofrequency coagulation of liver tumours. Br J Surg (2002) 3.39
A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology (2002) 2.90
Chemoembolization for hepatocellular carcinoma. Gastroenterology (2004) 2.89
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology (2004) 2.87
Hepatocellular carcinoma. J Hepatol (2000) 2.77
Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology (2002) 2.68
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl (2004) 2.65
Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology (1995) 2.63
Transplantation of liver grafts from living donors into adults--too much, too soon. N Engl J Med (2001) 2.61
Environmental factors and risk for hepatocellular carcinoma. Gastroenterology (2004) 2.47
Optimal therapy of hepatitis C. Hepatology (2002) 2.40
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
Hepatocellular carcinoma: recent trends in Japan. Gastroenterology (2004) 2.35
Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer (2003) 2.29
Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol (2000) 2.23
Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the "test-of-time approach". Cancer (2003) 2.22
Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology (2004) 2.16
Immune pathogenesis of hepatocellular carcinoma. J Exp Med (1998) 2.11
Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology (2004) 2.11
Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl (2003) 2.04
Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol (2001) 2.03
Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res (2002) 2.00
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol (1997) 1.85
How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer (2000) 1.68
Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer (2001) 1.68
Hepatocellular carcinoma: current surgical management. Gastroenterology (2004) 1.66
High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl (2004) 1.65
Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology (2003) 1.65
Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology (2004) 1.61
Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology (2004) 1.57
Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology (2001) 1.57
Trends in primary liver cancer. Lancet (1998) 1.56
Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med (2001) 1.53
Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet (2001) 1.52
Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol (2002) 1.52
Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology (2000) 1.49
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer (2001) 1.47
Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology (2004) 1.45
Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med (2000) 1.43
High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology (2002) 1.32
Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology (2004) 1.31
A plant-derived edible vaccine against hepatitis B virus. FASEB J (1999) 1.31
Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology (2004) 1.31
Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology (2004) 1.30
Prevention of hepatocellular carcinoma. N Engl J Med (2004) 1.27
An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology (2004) 1.24
Liver transplantation for hepatocellular carcinoma. Gastroenterology (2004) 1.24
Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology (2000) 1.23
Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology (2002) 1.22
Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis? Aliment Pharmacol Ther (1998) 1.21
Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis (1999) 1.21
The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl (2004) 1.20
Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol (2001) 1.17
DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. Vaccine (1996) 1.15
Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology (2004) 1.15
An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis (2004) 1.15
Diagnosis and staging of hepatocellular carcinoma. Gastroenterology (2004) 1.14
Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer (2000) 1.14
Treatment of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol (2005) 0.80